About: Comparison of an injectable toltrazuril-gleptoferron (Forceris®) and an oral toltrazuril (Baycox®) + injectable iron dextran for the control of experimentally induced piglet cystoisosporosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparison of an injectable toltrazuril-gleptoferron (Forceris®) and an oral toltrazuril (Baycox®) + injectable iron dextran for the control of experimentally induced piglet cystoisosporosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Comparison of an injectable toltrazuril-gleptoferron (Forceris®) and an oral toltrazuril (Baycox®) + injectable iron dextran for the control of experimentally induced piglet cystoisosporosis
Creator	Joachim, Anja Shrestha, Aruna Hinney, Barbara Freudenschuss, Barbara Karembe, Hamadi Palmieri, Nicola Sperling, Daniel
Source	Medline; PMC
abstract	BACKGROUND: Cystoisospora suis causes diarrhoeal disease and reduced weight gain in suckling piglets, and a toltrazuril-based oral suspension is available for treatment. Recently a combinatorial product with toltrazuril plus iron has been developed for parenteral application. In this study we compared the efficacy of the injectable product with the oral suspension against experimentally induced piglet cystoisosporosis. METHODS: In a randomised controlled study, three groups of piglets (n = 10–13) were treated either with a fixed dose of 45 mg toltrazuril + 200 mg gleptoferron i.m. per piglet (Forceris®) on the second day of life (study day 2; SD 2) or with 20 mg toltrazuril/kg body weight as an oral suspension (Baycox® 5%) on SD 4 or left untreated (Control group). The Baycox® and the Control group received 200 mg of iron dextran/piglet on SD 2. All piglets were infected with 1000 sporulated C. suis oocysts on SD 3. Faecal samples were taken daily from SD 7 to SD 20 to determine faecal consistency, oocyst shedding and other diarrhoeal pathogens. Body weight was recorded on SD 1 and then weekly until SD 29. Animals were observed daily for general health and after treatment for possible adverse events. RESULTS: In the Control group all animals shed oocysts for 3.1 days on average and all animals showed diarrhoea for an average of five days. Excretion peaked on SD 9 (max. 48,618 oocysts per gram of faeces). Treatment with Forceris® completely suppressed oocyst excretion. In the Baycox® group, low levels of excretion could be detected. Diarrhoea was reduced to single piglets in the treated groups. Body weight development was reduced in the Control group compared to the treated groups. Enteropathogenic bacteria (Escherichia coli, Clostridium perfringens) could be detected. All parameters related to oocyst excretion, faecal consistency and weight gain were significantly improved in the treated groups compared to the Control group without significant differences between the treated groups. Both products were safe to use. CONCLUSIONS: Treatment with both the injectable (Forceris®) and the oral (Baycox®) formulation of toltrazuril in the prepatent period were safe and highly effective against experimental infection with C. suis in newborn piglets.
has issue date	2018-03-27(xsd:dateTime)
bibo:doi	10.1186/s13071-018-2797-5
bibo:pmid	29580269
has license	cc-by
sha1sum (hex)	d29de422cabe325af2b7c85daeb5ee646aaef304
schema:url	https://doi.org/10.1186/s13071-018-2797-5
resource representing a document's title	Comparison of an injectable toltrazuril-gleptoferron (Forceris®) and an oral toltrazuril (Baycox®) + injectable iron dextran for the control of experimentally induced piglet cystoisosporosis
has PubMed Central identifier	PMC5870915
has PubMed identifier	29580269
schema:publication	Parasit Vectors
resource representing a document's body	covid:d29de422cabe325af2b7c85daeb5ee646aaef304#body_text
is schema:about of	named entity 'developed' named entity 'oral' covid:arg/d29de422cabe325af2b7c85daeb5ee646aaef304 named entity 'product' named entity 'piglets' named entity 'reduced' named entity 'efficacy' named entity 'parenteral' named entity 'Comparison' named entity 'parenteral' named entity 'Cystoisospora' named entity 'piglet' named entity 'toltrazuril' named entity 'iron dextran' named entity 'coprophagy' named entity 'excretion' named entity 'treatment groups' named entity 'coccidiosis' named entity 'France' named entity 'porcine' named entity 'diarrhoea' named entity 'diarrhoea' named entity 'Bayer Animal Health' named entity 'Escherichia coli' named entity 'excreted' named entity 'parasite' named entity 'Control group' named entity 'toltrazuril' named entity 'oocysts' named entity 'Control group' named entity 'Control group' named entity 'body weight' named entity 'piglet' named entity 'oocyst' named entity 'SD 12' named entity 'Virbac' named entity 'Microbiology' named entity 'toltrazuril' named entity 'toltrazuril' named entity 'blood volume' named entity 'bacterial infections' named entity 'Control group' named entity 'Oocyst' named entity 'SD 9' named entity 'diarrhoea' named entity 'coccidiosis' named entity 'Ringer's lactate' named entity 'treatment groups' named entity 'iucD' named entity 'Ceva' named entity 'excretion' named entity 'excretion' named entity 'virulence factor' named entity 'oocyst' named entity 'weaning' named entity 'Chi-square test' named entity 'excreted' named entity 'clinical signs' named entity 'toltrazuril' named entity 'oocysts' named entity 'diarrhoea' named entity 'diarrhoea' named entity 'diarrhoea' named entity 'piglet' named entity 'SD 1' named entity 'adverse events' named entity 'infection' named entity 'C. suis' named entity 'oocyst' named entity 'diarrhoea' named entity '5.0' named entity 'Control group' named entity 'excretion' named entity 'toltrazuril' named entity 'piglet'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software